HomeCompareCCSO vs ABBV

CCSO vs ABBV: Dividend Comparison 2026

CCSO yields 0.61% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $84.2K in total portfolio value
10 years
CCSO
CCSO
● Live price
0.61%
Share price
$25.65
Annual div
$0.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.5K
Annual income
$63.13
Full CCSO calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — CCSO vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCCSOABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CCSO + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CCSO pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CCSO
Annual income on $10K today (after 15% tax)
$51.58/yr
After 10yr DRIP, annual income (after tax)
$53.66/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,813.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CCSO + ABBV for your $10,000?

CCSO: 50%ABBV: 50%
100% ABBV50/50100% CCSO
Portfolio after 10yr
$62.6K
Annual income
$12,894.42/yr
Blended yield
20.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CCSO
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CCSO buys
0
ABBV buys
0
No recent congressional trades found for CCSO or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCCSOABBV
Forward yield0.61%3.12%
Annual dividend / share$0.16$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$20.5K$104.7K
Annual income after 10y$63.13$25,725.73
Total dividends collected$620.00$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CCSO vs ABBV ($10,000, DRIP)

YearCCSO PortfolioCCSO Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,761$60.68$11,559$438.51$798.00ABBV
2$11,575$61.03$13,494$640.86$1.9KABBV
3$12,447$61.35$15,951$945.97$3.5KABBV
4$13,379$61.66$19,152$1,413.89$5.8KABBV
5$14,378$61.94$23,443$2,146.38$9.1KABBV
6$15,447$62.21$29,391$3,321.96$13.9KABBV
7$16,590$62.46$37,948$5,265.87$21.4KABBV
8$17,814$62.70$50,795$8,596.74$33.0KABBV
9$19,124$62.92$71,034$14,549.41$51.9KABBV
10$20,526$63.13$104,715$25,725.73$84.2KABBV

CCSO vs ABBV: Complete Analysis 2026

CCSOStock

The fund is an actively-managed ETF that seeks to achieve its investment objective by investing primarily in U.S.-listed equity securities of companies that, in the Sub-Adviser’s opinion, are primarily focused on building solutions to address climate change. It may invest in international companies, including those in emerging markets, through U.S. exchange-tradedADRs, however, they will not be considered U.S. equity securities for purposes of the fund’s 80% policy.

Full CCSO Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CCSO vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CCSO vs SCHDCCSO vs JEPICCSO vs OCCSO vs KOCCSO vs MAINCCSO vs JNJCCSO vs MRKCCSO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.